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Sir,
We would like to thank Zanini et al (2010) for their critical
discussion of our data from a randomised phase II trial in locally
advanced pancreatic cancer (LAPC) that was recently published in
this journal (Wilkowski et al, 2009).
During the previous years, LAPC has been increasingly
recognised as a separate disease entity in malignant pancreatic
disorders. With the use of systemic gemcitabine-based chemo-
therapy, LAPC has a favourable survival prognosis compared with
metastatic pancreatic cancer; however, the value of chemo-
radiotherapy still remains controversial in this stage of disease
(Chauffert et al, 2008). We fully agree with Zanini et al that a
unique, internationally standardised and accepted definition of
LAPC is not yet established to date, and that such an approach is
strongly recommend for future clinical trials in LAPC. Currently,
different study groups still apply individual definitions for LAPC
(Chauffert et al, 2008; Crane et al, 2009) and this definition
probably is still mostly influenced by the definition of ‘resecta-
bility’ of the involved surgeon. A first step for the formulation of
standardised criteria defining the respectability status in pancrea-
tic cancer (e.g., ‘resectable’ vs ‘borderline resectable’ vs ‘unresect-
able’) is included in the current version of the NCCN guidelines for
pancreatic adenocarcinoma (http://www.nccn.org, V.I.2009).
At the time when our phase II study was designed in 2001, the
criteria for defining LAPC included in the study protocol were a
first attempt to standardise the LAPC definition in the setting of a
prospective multi-centre clinical trial. However, the authors are
fully aware of the limitations of such an approach, as critically
formulated by Zanini et al. In fact, much more future research will
be necessary in order to better characterise LAPC clinically and
biologically. Besides, currently – as recently reported in a study by
Morak et al – the classification of a tumour as LAPC may still
depend on the diagnostic possibilities and on the experience of a
clinical institution (Morak et al, 2009).
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